Brind.
  1. The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.

FDA placed a clinical hold on RGX-121 trials, leading to a sharp decline in REGENXBIO Inc.'s stock price.

1 report, 1 independent Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

FDA placed a clinical hold on RGX-121 trials, leading to a sharp decline in REGENXBIO Inc.'s stock price.

Who's involved

What this event is mainly about
FDA

Keep exploring

Part of

The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped